相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current and emerging therapeutic targets for IBD
Markus F. Neurath
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease
Suhrid Banskota et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
Caroline Meyer Olesen et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Integrins and adhesion molecules as targets to treat inflammatory bowel disease
Ivana Bravata et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
The global burden of IBD: from 2015 to 2025
Gilaad G. Kaplan
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Giovanni Monteleone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP ldnase with reduced side effects based on the antedrug concept
Koichi Hasumi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201
Nobuhiko Hayakawa et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
New Drugs on the Horizon for IBD
Bruce E. Sands
DIGESTIVE DISEASES (2014)
6-Amino-2,4,5-trimethylpyridin-3-ols: A new general synthetic route and antiangiogenic activity
Dong-Guk Kim et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Protective effect of 7-O-succinyl macrolactin A against intestinal inflammation is mediated through PI3-kinase/Akt/mTOR and NF-κB signaling pathways
Sumin Park et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
Mariangela Allocca et al.
CURRENT DRUG TARGETS (2013)
Keeping the Bowel Regular: The Emerging Role of Treg as a Therapeutic Target in Inflammatory Bowel Disease
David J. Gibson et al.
INFLAMMATORY BOWEL DISEASES (2013)
Regioselective Synthesis of 2-Amino-Substituted 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives via Reagent-Based Cyclization of Thiosemicarbazide Intermediate
Seung-Ju Yang et al.
JOURNAL OF ORGANIC CHEMISTRY (2013)
IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells
Margherita Coccia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
IL-10 and IL-10 receptor defects in humans
Erik-Oliver Glocker et al.
YEAR IN HUMAN AND MEDICAL GENETICS: INBORN ERRORS OF IMMUNITY II (2011)
Genetics and pathogenesis of inflammatory bowel disease
Bernard Khor et al.
NATURE (2011)
IL-10: The master regulator of immunity to infection
Kevin N. Couper et al.
JOURNAL OF IMMUNOLOGY (2008)
Clotrimazole Ameliorates Intestinal Inflammation and Abnormal Angiogenesis by Inhibiting Interleukin-8 Expression through a Nuclear Factor-κB-Dependent Manner
Dinesh Thapa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Recent understanding of IBD pathogenesis:: Implications for future therapies
Torsten Kucharzik et al.
INFLAMMATORY BOWEL DISEASES (2006)
Inhibition of E-cadherin-mediated homotypic adhesion of Caco-2 cells: A novel evaluation assay for peptide activities in modulating cell-cell adhesion
N Kobayashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer
R Atreya et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2005)
分享论文
